Top Markets
Coin of the day
Pascal Biosciences Inc. Pascal Biosciences Inc.

Pascal Biosciences Inc.

PSCBF
Classifica tra le azioni #37975
Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to... Pascal Biosciences Inc. is an innovative biopharmaceutical firm dedicated to discovering and advancing therapeutic solutions for oncology and bolstering immune system function. The company's robust pipeline includes several key candidates: PAS-403, a potent mitosis inhibitor designed to impede cancerous cell division, specifically targeting glioblastoma and secondary brain tumors; and PAS-393, an immunomodulatory cannabinoid developed to enhance the immune system's recognition of tumor cells when utilized alongside checkpoint inhibitor therapy. Furthermore, Pascal is progressing a specialized antibody therapy aimed at B-cells, intended for conditions like acute lymphoblastic leukemia and various B-cell lymphomas. The company is also investigating cannabinoid-derived products as potential treatments for COVID-19. To support its research, Pascal Biosciences maintains an exclusive licensing agreement with the University of Washington for a cannabinoid-based therapeutic against glioblastoma multiforme and brain metastases. It also benefits from a collaborative research partnership with SoRSE Technology Corporation, focused on advancing PAS-393 toward clinical trials. Founded in 2011, the company operates from its headquarters in Seattle, Washington.
Prezzo delle azioni
$0.1
Ultima sincronizzazione: 2024-06-18
Capitalizzazione di mercato
$1.31M
Variazione (1 giorno)
0.00%
Variazione (1 anno)
0.00%
Paese
US
Scambia Pascal Biosciences Inc. (PSCBF)

Categoria

Utile per Pascal Biosciences Inc. (PSCBF)
Utile nel Feb 2024 TTM: $-247.59K
Secondo gli ultimi rapporti finanziari di Pascal Biosciences Inc., gli utili attuali della società sono $-247.59K. Nel 2022, la società ha registrato un utile di $-359.87K, un aumento rispetto a agli utili del 2021, che erano di $-853.00K. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Pascal Biosciences Inc. dal 2019 al 2026
Utile alla fine di ogni anno
Anno Utile Cambia
2026 (TTM) $-247.59K -15.84%
2023 $-294.20K -18.25%
2022 $-359.87K -57.81%
2021 $-853.00K -9.78%
2020 $-945.48K -63.20%
2019 $-2.57M 0.00%
Utile per aziende simili o concorrenti
Azienda Utile Differenza negli utili Il paese
$5.27B -2,130,610.56%
US
$1.95B -787,959.61%
NL
- -
CH
- -
KR
$3.01B -1,214,096.90%
BE